SCHEMBL29348781

SCHEMBL29348781

O=c1c(C(F)(F)F)cccn1-c1ccc(Br)cc1

nearest known ligand 0.41

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
HTT P42858 1/20 0.41
KMT2A Q03164 1/20 0.41
MAPT P10636 4/20 0.38
RXFP1 Q9HBX9 2/20 0.38
PKM P14618 1/20 0.36
TRPV1 Q8NER1 2/20 0.36
FFAR4 Q5NUL3 2/20 0.36
NPC1 O15118 1/20 0.36
RAB9A P51151 1/20 0.36
FAAH O00519 1/20 0.35
MGLL Q99685 1/20 0.35
CA2 P00918 1/20 0.35
NPSR1 Q6W5P4 1/20 0.34
TP53 P04637 2/20 0.33
LMNA P02545 1/20 0.33
POLB P06746 1/20 0.33
NFKB1 P19838 1/20 0.33
GPR183 P32249 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10691031 0.86 TRPV1 (0.44) MAPTRXFP1TRPV1CA2NPSR1
SCHEMBL10059739 0.84 MAPT (0.44) HTTKMT2AMAPTRXFP1CA2
SCHEMBL31537714 0.81 ALDH1A1 (0.40) MAPTRXFP1TP53LMNAPOLB
SCHEMBL31537633 0.80 VHL (0.42) MAPTRXFP1CA2TP53LMNA
SCHEMBL29348940 0.76 KMT2A (0.38) HTTKMT2AMAPTRXFP1PKM
SCHEMBL30827615 0.74 CYP3A4 (0.41) HTTKMT2AMAPTLMNA
SCHEMBL29348938 0.74 KMT2A (0.39) HTTKMT2AMAPTPKMFAAH
SCHEMBL27250754 0.74 FFAR4 (0.41) TRPV1FFAR4TP53POLB
SCHEMBL29348937 0.71 KMT2A (0.45) HTTKMT2AMAPTPKMFAAH
SCHEMBL21017007 0.71 CYP3A4 (0.36) MAPTRXFP1TRPV1POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4648853-A1 TARGETED DEGRADATION OF VAV1 Monte Rosa Therapeutics AG (CH) 2025-11-19 EP disclosed
US-20250205219-A1 TARGETED DEGRADATION OF VAV1 MONTE ROSA THERAPEUTICS AG (CH) 2025-06-26 US disclosed
WO-2024151547-A1 TARGETED DEGRADATION OF VAV1 MONTE ROSA THERAPEUTICS, INC. (US) 2024-07-18 WO disclosed
WO-2024151547-A1 TARGETED DEGRADATION OF VAV1 MONTE ROSA THERAPEUTICS, INC. (US) 2024-07-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250205219-A1 TARGETED DEGRADATION OF VAV1 VAV1, KRAS, CBL HTT 2340/4885KMT2A 1159/4885MAPT 3092/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.